替诺福韦二吡呋酯

{{Infobox drug
| image = Tenofovir disoproxil structure.svg
| image_class = skin-invert-image
| width = 260
| alt = Above: molecular structure of tenofovir disoproxil
Below: 3D representation of a tenofovir disoproxil molecule
| image2 = Tenofovir disoproxil 3D.png
| image_class2 = bg-transparent
| pronounce =
| tradename = Viread及其他
| Drugs.com =
| MedlinePlus = a602018
| DailyMedID = Tenofovir disoproxil
| pregnancy_AU = B3
| routes_of_administration = 口服給藥
| class =
| ATC_prefix = J05
| ATC_suffix = AF07
| legal_AU = S4
| legal_AU_comment =
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_EU = Rx-only
| legal_EU_comment =

| bioavailability = 25%
| protein_bound =
| metabolism =
| metabolites = 替諾福韋
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
| CAS_number = 201341-05-1
| PubChem = 5481350
| DrugBank = DB00300
| ChemSpiderID = 4587262
| UNII = F4YU4LON7I
| KEGG = C13480
| ChEBI = 63717
| ChEMBL = 1538
| NIAID_ChemDB = 080741
| synonyms = Bis(POC)PMPA

| IUPAC_name = Bis{[(isopropoxycarbonyl)oxy]methyl} ({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)phosphonate
| C = 19
| H = 30
| N = 5
| O = 10
| P = 1
| SMILES = CC@HOCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
| StdInChI = 1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1
| StdInChIKey = JFVZFKDSXNQEJW-CQSZACIVSA-N
}}

{{Drugbox
| drug_name = 替諾福韋
| Watchedfields = changed
| verifiedrevid = 461742056
| image = Mbg inc.Tenofovir.svg
| image_class = skin-invert-image
| width = 200
| alt =

| MedlinePlus = a602018
| routes_of_administration =
| ATC_prefix = None
| ATC_suffix =

| protein_bound =

吉利德科學隨後開發第二種活性藥物的前藥形式，稱為'泰諾福韋艾拉酚胺' (Tenofovir alafenamide，簡稱'TAF')。它與'TDF'的不同之處在於其主要在'淋巴細胞'中被活化。使得活性代謝物能積聚在這些細胞中，進而降低全身性的藥物暴露量，並減少潛在的毒性反應。

引用文獻
碳酸酯
吉利德科學
肝毒素
異丙酯
殺微生物劑
核苷類似物逆轉錄酶抑制劑
前藥
嘌呤
世界衛生組織基本藥物
RTT